Mineralys Therapeutics (MLYS) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Schrodinger (SDGR) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 35.4% versus a loss of 41.3%. Schrodinger is the larger company by market cap ($2.04 billion vs $1.95 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | SDGR |
|---|---|---|
| Share price | $22.09 | $27.29 |
| Market cap | $1.95B | $2.04B |
| 1-day change | +0.64% | -5.57% |
| YTD return | -39.13% | +52.63% |
| 1-year return | -41.34% | +35.37% |
| 5-year return | — | -50.70% |
| EPS (TTM) | $-4.25 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $47.65 | $33.78 |
| 52-week low | $21.50 | $10.95 |
| Distance from 52-week high | -53.64% | -19.21% |
| Analyst consensus | none | none |
| Avg. price target upside | +119.56% | -21.47% |
| Average volume | 1.03M | 1.69M |
| Shares outstanding | 88.41M | 65.64M |
| Employees | 76 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SDGR has outperformed MLYS by 76.7 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
MLYS vs SDGR FAQ
Which is bigger, Mineralys Therapeutics or Schrodinger?
Schrodinger (SDGR) is larger, with a market capitalization of $2.04B compared with $1.95B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, MLYS or SDGR?
SDGR returned +35.37% over the past 12 months, compared with -41.34% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.